13856 research outputs found
Sort by
作为极光激酶抑制剂的稠合双环嘧啶化合物
No full text[[abstract]]本发明关于式(I)的稠合双环嘧啶化合物。本发明也公开一种抑制极光激酶活性的方法，以及一种用这些化合物治疗癌症的方法。Fused bicyclic pyrimidine compounds of formula (I): wherein R1, R3, R4, X1, X2, Y, Z, A, B, C, D, n, and the two bonds are defined herein. Also disclosed are a method for inhibiting Aurora kinase activity and a method for treating cancer with these compounds
苯並咪唑化合物及其在製備治療阿茲海默症或亨丁頓氏症的藥物中的用途
No full text[[abstract]]本发明提供了一种如式(I)所示的苯并咪唑化合物，该化合物是有效的人类麸酸胺环化酶抑制剂。本发明还提供了一种含有该等化合物中之一化合物及医药上可接受载体的医药组合物以及一种藉由对需要治疗阿兹海默症或亨丁顿氏症的个体投予有效量的该化合物来治疗阿兹海默症或亨丁顿氏症的方法
Proline derivatives for use to treat hepatitis c infection
No full text[[abstract]]Compounds of formula (I) shown in the specification. Also disclosed is a method for treating hepatitis C virus infection with these compounds
噻唑烷酮化合物及其用途
No full text[[abstract]]一种包含式(I)化合物的用于治疗阿片样物质受体相关病症的药物组合物。也公开了使用这种化合物治疗阿片样物质受体相关病症的方法。进一步公开了两组式(I)的噻唑烷酮化合物：(i)各自具有大于90％对映体过量值的化合物以及(ii)各自经氘取代的化合物
オピオイド受容体調節因子及びその使用
No full text[[abstract]]Disclosed is an in vitro screening method for identifying an antagonist-to-agonist allosteric modifier of a mu-opioid receptor and an in vivo method for confirming that a test compound is such a modifier of a mu-opioid receptor. Also disclosed is a method for treating an opioid receptor-associated condition using a compound of Formula (I) and a pharmaceutical composition containing the same
Aminothiazole compounds and use thereof
No full text[[abstract]]Aminothiazole compounds of Formula (I) shown herein and pharmaceutical compositions containing one of such compounds
吡咯烷化合物
No full text[[abstract]]本發明涉及一種具有如下結構式的化合物：其中R1、R2、R3、R4、R5、R6、X、Y、Z、m、n以及p的定義請見說明書，本發明還涉及用該化合物抑制二肽基肽酶IV或VIII，或者治療II型糖尿病的方法
[[alternative]]Use of compound for preparing medicament of treating cdgsh iron sulfur domain 2 insufficiency-associated disorders
No full text[[abstract]]本發明揭露一種治療Cisd2不足相關病症的方法。該方法包含向有需要的一主體施用式(I)化合物。也揭露了一種增加Cisd2基因表現的方法
[[alternative]]Method for diagnosing and treating asthma by detecting or regulating a panel of internal lipid species
No full text[[abstract]]本發明提供一種透過使用一組體內脂質種類以診斷哮喘的方法，其中該體內脂質種類包含LPE 22:6、LPE 20:4、SM 16:0、PE 16:0/22:6、PE 18:0/22:6、PE 18:0/20:4、PE 18:0/18:2、與磷脂膽鹼(PC) 18:0/18:2，該方法係包含將該組體內脂質種類的一截斷比率值(cutoff ratio value)與受試者的體內脂質種類比率進行比較。本發明亦提供一種治療哮喘的方法，包含給予有需要的患者一有效劑量的LEP22:6抑制性調節劑、牛血清白蛋白或人類血清白蛋白
High expression of CD80 promotes cell growth and stemness of oral squamous cell carcinoma cells
No full text[[abstract]]Oral squamous cell carcinoma (OSCC) is a leading cause of morbidity and mortality in head and neck cancer patients. To evaluate the immunotherapy of OSCC in East Asian, we established a novel cell line, named NHRI-HN1, from a mouse tongue tumor induced by 4-NQO/arecoline. M1-2sph-T (sphT)and M1-2sph-N (sphN) cells were derived from orthotopic tumors and cervical lymph nodes of mice injected with NHRI-HN1 cells, respectively. Compared to NHRI-HN1 cells, sphT and sphN cells displayed faster tumor growth in mice, along with increased cell growth, migration, and sphere formation. These cells also showed enhanced activation of ERK and markers of EMT. Based on the gene expression array analysis, we found that both sphT and sphN cells showed higher expression levels of CD80 as compared with NHRI-HN1 cells. Knockdown of CD80 inhibited sphere formation and tumor growth of mouse OSCC cells. Also, the sphere formation and tumor growth were enhanced in mouse OSCC cells with high expression of CD80. We found CD80 expression was correlated with the expression of Sox2 and CD274 in mouse OSCC cells. The relationship among CD80, Sox2 and CD274 in OSCC cells was under investigation